Novavax (NVAX) Stock
Clinical stage biotech developing protein vaccines. Here's the price, business snapshot, and what's worth knowing about Novavax in October 2026.
Novavax, Inc. (NVAX) is a clinical‑stage biotechnology company focused on developing protein‑based vaccines, best known for its COVID‑19 vaccine candidate NVX‑CoV2373. Investors should know Novavax’s fortunes are closely tied to the progress of its pipeline, contract and grant revenues, and its ability to secure regulatory approvals and manufacturing scale. The company has a history of funding rounds and collaborations with governments and partners, which can boost near‑term cash flow but also create revenue lumpiness. Key risks include clinical trial outcomes, regulatory decisions, competitive vaccine platforms, and the need for additional capital to support R&D and commercialisation. With a market capitalisation of about $1.40B, Novavax may offer growth upside for those who believe in its technology, but it is also a higher‑volatility, higher‑risk equity more suitable for investors comfortable with biotech uncertainty. This is educational information, not personalised investment advice.
Novavax (NVAX) Stock Forecast
Analyst price target, next 12 months
$16.64
+59.0% vs today's $10.46
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Novavax have a consensus 12-month target of $16.64, above the current price of $10.46.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Novavax stock, anticipating a price increase to $16.64 in the future.
Financial Health
Novavax is generating strong profits and revenue, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline and R&D
Novavax's future depends on clinical progress and approvals; successful trials can drive value, though outcomes are uncertain and can affect share price sharply.
Contract‑Led Revenue
Government and partner deals have been a major revenue source, offering near‑term visibility but also creating lumpiness and dependence on external funding.
Manufacturing & Scale
Scaling production is central to commercial success; manufacturing or supply hiccups can delay launches and revenue, so operational risk is material.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
